| 摘要 |
1. The use of eletriptan, or of a pharmaceutically acceptable salt or composition thereof, for the manufacture of a medicament for the prevention of migraine recurrence. 2. Use as claimed in claim 1 wherein the salt is a hydrobromide salt. 3. Use as claimed in claim 1 wherein the salt is a hemisulphate salt. 4. Use as claimed in claim 1 wherein the medicament comprises eletriptan hemisulphate and caffeine. 5. Use as claimed in claim 1 wherein the medicament comprises eletriptan, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. 6. Use as claimed in claim 1 wherein the medicament is a dual-, sustained-, controlled-, delayed- or pulsed-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 7. Use as claimed in claim 6 wherein the medicament is a dual-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 8. A method for preventing of migraine recurrence comprising administering a patient in need an effective amount of eletriptan, or a pharmaceutically acceptable salt or composition thereof. 9. The method as claimed in claim 8 wherein the salt is a hydrobromide salt. 10. The method as claimed in claim 8 wherein the salt is a hemisulphate salt. 11. The method as claimed in claim 8 wherein the composition comprises eletriptan hemisulphate and caffeine. 12. The method as claimed in claim 8 wherein the composition comprises eletriptan, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. 13. The method as claimed in claim 8 wherein the composition is a dual-, sustained-, controlled-, delayed- or pulsed-release formulation of eletriptan or a pharmaceutically acceptable salt thereof. 14. The method as claimed in claim 8 wherein the composition is a dual-release formulation of eletriptan or a pharmaceutically acceptable salt thereof.
|
